Post-operative anti-HER2 IHC analysis showed 10/11 specimens had low HER2 expression levels with incomplete/weak membrane staining in > 10% of tumor cells (corresponding to a pathological score of 1 + , which is clinically considered HER2-negative) and one specimen to have amplified HER2 expression levels, characterized by circumferential membrane staining that is complete/strong in > 10% of tumor cells (score of 3 + , clinically HER2-positive). This evidence concerns the gene ERBB2 and neoplasm.